ChiCTR2600125945 Sunvozertinib KRAS G12C NSCLC Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook

Move from a broad disease map to a decision-ready trial dossier. This focused report examines ChiCTR2600125945—A Prospective, Open-Label, Umbrella, Phase II Study of Lucamtasutab for Injection Combined with Targeted Therapy as Neoadjuvant Treatment for Non-Small Cell Lung Cancer Harboring Rare Mutations—using PatSnap Clinical Trials, Drug & Asset, and Company & Deal Intelligence MCP evidence. Explore PatSnap MCP Servers to reproduce the workflow inside an AI research process.

MCP evidence snapshot: 16 July 2026; publication date: 17 July 2026. Trial records can change after the snapshot and should be rechecked before operational decisions.

Why ChiCTR2600125945 is a hot trial to watch

KRAS G12C NSCLC is no longer one homogeneous development market. The most consequential programs increasingly compete through a specific mechanism, biomarker, treatment line, delivery strategy or endpoint architecture. ChiCTR2600125945 is notable because it tests Sunvozertinib, Pralsetinib, Garsorasib in a Phase 2 design with MPR rate as a primary decision variable. The wider PatSnap topic query returned 97 trial records and 114 result records, so differentiation depends on evidence quality rather than activity alone.

PatSnap Clinical Trials MCP makes the protocol fields machine-readable, while the companion asset and organization servers add mechanism and sponsor context.

Trial landscape snapshot

Design and endpoint interpretation

The design should be read as an evidence architecture, not just a phase label. The primary endpoint—MPR rate—determines what uncertainty this study can resolve. The reported time frame is Following the completion of neoadjuvant therapy. Enrollment of 14 participants and geography in China shape statistical precision, operational risk and external validity. A strong readout will need to be interpreted against baseline risk, prior treatment, assessment schedule, missing-data handling and the clinical relevance of the observed effect.

Benchmark readouts in the same clinical field

• A Phase 2, Multicenter, Open-label Study of Sotorasib (AMG 510) in Subjects With Stage IV NSCLC Whose Tumors Harbor a KRAS G12C Mutation in Need of First-line Treatment (CodeBreaK 201) (Phase 2): -; -; -; Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) = 26.8 percentage of participants (95% Confidence Interval, 14.2 - 42.9); -.
• Elisrasib (D3S-001), a next-generation GDP-bound KRAS G12C inhibitor, as first-line therapy for KRAS G12C mutation–positive non–small cell lung cancer (NSCLC). (Phase 1/2): DoR(6-month) = 80.5 % ; DoR(6-month) = 77.2 % .
• Cost per patient per month for a median of 3 months: Real-world value signals of KRAS^G12C inhibitors in U.S. claims for non–small cell lung cancer. (Not Applicable): Adverse-event-related claims = 40.0 % .

These result records are contextual benchmarks rather than direct head-to-head evidence. Cross-trial comparisons can be distorted by population, line of therapy, endpoint definition, follow-up and analysis set. Their value is to clarify what magnitude and type of evidence the market already recognizes.

Build a living trial monitor: connect to PatSnap MCP Servers and track protocol changes, primary-completion dates and newly indexed results without manually reconciling separate databases.

Asset and sponsor context

Drug & Asset context: Sunvozertinib (Approved; EGFR exon 20 x HER2 exon 20); Pralsetinib (Approved; RET); Garsorasib (Approved; KRAS G12C).

Company & Deal Intelligence context: Zhejiang Cancer Hospital — https://www.zchospital.com.

The sponsor profile matters because a trial's strategic value depends on more than scientific rationale. Manufacturing readiness, portfolio fit, geographic reach, partnering capacity and the ability to fund confirmatory development can determine whether a positive signal becomes a competitive asset.

White space around this program

1. Sharper patient selection: prospective biomarker definitions that identify who is most likely to benefit.
2. Clinically interpretable endpoints: outcomes that connect biological activity with function, symptoms, survival or treatment burden.
3. Sequencing evidence: randomized data after the most relevant contemporary standard of care.
4. Broader external validity: evidence across additional geographies, demographic groups and real-world care settings.
5. Operational differentiation: a development path that closes the readout gap without sacrificing safety monitoring or durability.

What to monitor next

Monitor recruitment status, enrollment changes, protocol amendments, endpoint hierarchy, primary-completion timing, first result indexing, asset ownership and sponsor partnerships. The most important inflection point is not always the headline data release; a change in endpoint, population or ownership can alter probability of success months earlier.

Bottom line

ChiCTR2600125945 is a focused lens on KRAS G12C NSCLC development. Its value will be determined by whether Sunvozertinib can convert the current design into evidence that is clinically meaningful, operationally credible and differentiated from topic-level benchmark readouts.

Ready to reproduce this analysis? Explore PatSnap MCP Servers and combine Clinical Trials, Drug & Asset, and Company & Deal Intelligence as reusable building blocks for trial monitoring and SEO-ready clinical reports.